<DOC>
	<DOCNO>NCT02756104</DOCNO>
	<brief_summary>ALS devastative disorder characterize motor neuron degeneration . Median survival 3 year onset , may vary month 30 year . Various factor suspect play role variation , recently , describe regulatory T-lymphocytes ( T regs ) may mediate ALS progression survival . Vitamin D hormone know regulate T reg function vivo vitro . It recently demonstrate vitamin D ( VD ) level correlate ALS prognosis . The investigator want go study immune process could modulate prognosis ALS . This could allow propose VD potential treatment ALS future trial . More largely , could reinforce argument favor immune intervention attenuate severity devastate disorder .</brief_summary>
	<brief_title>T Cell Phenotypes Amyotropic Lateral Sclerosis ( ALS ) , Influence Vitamin D</brief_title>
	<detailed_description>ALS devastative disorder characterize motor neuron degeneration . Median survival 3 year onset , may vary month 30 year . Various factor suspect play role variation , recently , describe regulatory T-lymphocytes ( T regs ) may mediate ALS progression survival . Vitamin D hormone know regulate T reg function vivo vitro . It recently demonstrate vitamin D ( VD ) level correlate ALS prognosis patient severe VD deficiency 6 time rapid evolution normal VD level . The investigator want go study immune process could modulate prognosis ALS . We propose 1- study T cell phenotype ( Treg , CD4 ( cluster differentiation 4 ) -Th1 , -Th17 , -Th2 , CD8 ( cluster differentiation 8 ) NK ) ALS v control ; 2- In VD-deficient patient , analyze influence vitamin D supplementation T cell phenotype ; 3- study relationship T cell phenotype ALS prognostic factor . The project include 70 ALS patient 27 control prospective study . VD-deficient patient supplement , accord national recommendation 6 month , evolution T cell phenotype follow 1 year . We hope demonstrate first T cell phenotype ALS consistent pro inflammatory profile , compare control , secondly VD treatment modulate T cell phenotype towards non-inflammatory one , thirdly , inflammatory T cell phenotype correlate bad prognosis disease . This could allow propose VD potential treatment ALS future trial . More largely , could reinforce argument favor immune intervention attenuate severity devastate disorder .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>For patient : Man woman sporadic ALS possible , probable definite diagnosis regard revise Escorial criterion ( Forbes et al. , 2001 ) . Patients follow quarterly accord national recommendation . At end follow period ( 1 year patient ) , patient remain `` possible `` group diagnosis exclude . Disease onset ( date onset muscle weakness ) &lt; 18 month time inclusion . Age : 30 80 yearsold , inclusive . Patient treat riluzole steady dosage since least 3 month . Patient accept give inform consent Exclusion criterion : A previous treatment VD precede 2 year , whatever dose use . Patient already know autoimmune disorder Patient severe ALS involvement suggest survival 1 year follow highly unlikely ( ex : tetraplegia , use noninvasive ventilation 10 hrs/day , ALSFRSR ( ALS Functional Rating Scale ) score &lt; à 20 ) . Pregnant breastfeed woman . Patient without social security insurance For Controls : Controls spouses ALS patient . Such group advantage similar life style condition , frequently similar geographical origin . Controls ALS patient match age gender . Controls also fulfill follow inclusion exclusion criterion Inclusion criterion •Subject accept give inform consent Exclusion criterion Subject already know neurodegenerative disorder Subject already know autoimmune disorder Subject receive treatment VD precede 2 year , whatever dose use . Pregnant breastfeed woman Subject without social security insurance</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>